title: Use of fibrin-based sealants and gelatin-matrix hemostats in laparoscopic liver surgery.
abstract: BACKGROUND
  During surgery, liver tissue is particularly prone to bleeding which can be difficult to control, especially in patients with liver disease-associated coagulopathy. Topical sealants and hemostats can enhance clot formation and wound healing, and can be useful for controlling or preventing troublesome bleeding during surgical interventions where conventional methods of hemostasis are inadequate.
  
  
  METHODS
  An extensive customized literature search was conducted using medical reference databases to identify publications related to the use of potential agents in laparoscopic liver surgery. Citations from these articles were also used. Details of the authors' own experience in this area is also included.
  
  
  RESULTS
  Routine use of fibrin-based sealants in open liver surgery now seems to be widespread. Data from several large prospective randomized controlled clinical trials have indicated that application of fibrin-based sealants to the cut liver surface during hepatectomy does provide some benefit in terms of a shorter time to hemostasis and a reduction in postoperative drainage fluid, even when compared with argon beam coagulation. Another trial found no additional benefit of fibrin sealants when applied after coagulation of the cut liver surface. A prospective, uncontrolled study found that application of the flowable gelatin matrix-based hemostat Floseal provided rapid effective control of mild-to-severe bleeding during surgical removal of primary or metastatic liver tumors, even in those with cirrhosis. Some of these topical hemostatic agents are already being used on a routine basis by many surgeons performing laparoscopic liver surgery. Although there are no randomized clinical trials, there are several anecdotal or case reports of their effective use during laparoscopic liver surgery.
  
  
  CONCLUSIONS
  On the basis of current evidence of using hemostats and sealants in open liver surgery, there is potential of developing these strategies in laparoscopic liver surgery.
authors.affiliation: Department of Hepatobiliary and Liver Transplant Surgery, Freeman Hospital, Newcastle upon Tyne, UK.
authors.forename: Rehan
authors.initials: R
authors.lastname: Saif
authors.forename: Mathew
authors.initials: M
authors.lastname: Jacob
authors.forename: Stuart
authors.initials: S
authors.lastname: Robinson
authors.forename: Amien
authors.initials: A
authors.lastname: Amer
authors.forename: Douglas
authors.initials: D
authors.lastname: Kei-Hui
authors.forename: Gourab
authors.initials: G
authors.lastname: Sen
authors.forename: Derek
authors.initials: D
authors.lastname: Manas
authors.forename: Steve
authors.initials: S
authors.lastname: White
mesh_terms: D000287:Administration, Topical; D001672:Biocompatible Materials; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage*; D005340:Fibrinogen / Q000008:administration & dosage*; D006489:Hemostatic Techniques; D006490:Hemostatics / Q000008:administration & dosage*; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D010535:Laparoscopy; D008107:Liver Diseases / Q000601:surgery; D015503:Surgical Sponges; D013917:Thrombin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D001672:Biocompatible Materials; D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; D006490:Hemostatics; C518955:TachoSil; D005340:Fibrinogen; D013917:Thrombin